Ignite Creation Date:
2024-05-06 @ 12:32 AM
Last Modification Date:
2024-10-26 @ 10:50 AM
Study NCT ID:
NCT01591109
Status:
COMPLETED
Last Update Posted:
2012-05-03
First Post:
2012-05-02
Brief Title:
A Reversal in the Vascularity of Metastatic Liver Tumors From Colorectal Cancer After the Cessation of Anti-VEGF Therapy
Sponsor:
NHO - Matsumoto Medical Center
Organization:
NHO - Matsumoto Medical Center
Study Overview
Official Title:
A Reversal in the Vascularity of Metastatic Liver Tumors in Patients With Colorectal Cancer After the Cessation of Anti-VEGF Therapy A Study Using Contrast-enhanced Ultrasonography and Histological Techniques
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Objective To assess the effect of bevacizumab on tumor vessels and the reversibility of the effect using contrast-enhanced ultrasonography CEUS and histology in patients with metastatic liver tumors derived from colorectal cancer
Background Data Direct evidence on the reversibility of any change in tumor vascularity upon bevacizumab cessation in the clinical setting is lacking
Methods The study included 10 patients who received chemotherapy including bevacizumab experienced a reduction in tumor vascularity as demonstrated by CEUS and consequently underwent liver resection CEUS was performed before and immediately after 4 courses of chemotherapy and one day before surgery The number of microvessels highlighted by anti-CD34 antibody in the viable tumor tissue was counted to quantify the microvessel density MVD As a control 10 surgical specimens from 10 patients who had not received chemotherapy were examined
Background Data Direct evidence on the reversibility of any change in tumor vascularity upon bevacizumab cessation in the clinical setting is lacking
Methods The study included 10 patients who received chemotherapy including bevacizumab experienced a reduction in tumor vascularity as demonstrated by CEUS and consequently underwent liver resection CEUS was performed before and immediately after 4 courses of chemotherapy and one day before surgery The number of microvessels highlighted by anti-CD34 antibody in the viable tumor tissue was counted to quantify the microvessel density MVD As a control 10 surgical specimens from 10 patients who had not received chemotherapy were examined
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None